Product Name:
Cot (Cot-1)
Product Number:
ab-nk042-1
Target Full Name: Osaka thyroid oncogene protein-serine kinase (Tpl2); Mitogen-activated protein kinase kinase kinase 8
Target Alias: FLJ10486; M3K8; MAP3K8; Tpl2; TPL2; TPL-2; tumour progression locus 2; Cot; ESTF; EST; Tpl-2; c-Cot; ENSG00000107968
Product Type Specific: Cot (Tpl2) protein kinase pan-specific antibody
Antibody Code: NK042-1
Antibody Target Type: Pan-specific
Protein UniProt: P41279
Protein SigNET: Cot
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Cot (MAP3K8, TPL2) sequence peptide
Antibody Immunogen Sequence: MEYMSTGSDNKEEIDC
Antibody Immunogen Description: Corresponds to amino acid residues M1 to D15; N-terminus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Cot expressed in E. coli as a glutathione S transferase fusion protein.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Antibody Cross Reactivity: Cross-reacts with an unidentified 30 kDa protein in rat skeletal muscle.
Related Product 1: Cot expression antibody (Cat. No.: AB-NK042-2)
Related Product 2: Cot T290 phosphorylation antibody (Cat. No.: AB-PK956)
Related Product 3: Cot S334 phosphorylation antibody (Cat. No.: AB-PK585)
Scientific Background: Cot (TPL2, MAP3K8) is a protein-serine/threonine kinase of the STE group and STE-Unique family. It activates the MEK/ERK pathway by phosphorylating MEK1/2, a key step in inflammation and proliferation. It is described as a unique MAPKKK that can act simultaneously on all known MAPK cascades, including JNK, p38, and ERK5. Cot is essential for producing pro-inflammatory cytokines, specifically activating the signaling pathway for tumor necrosis factor-alpha (TNF-alpha) n macrophages and T lymphocytes. It is also implicated in IL-2 production during T-cell activation. It is essential in the TLR4 (recognizing LPS) MAPK/ERK-mediated response in the production of pro-inflammatory cytokines. The catalytic activity of Cot is lost with the K167R, or D270A mutations. IL-1 stimulated activity is decreased with S62A. This mutation will also inhibit IL-1 stimulated phosphorylation of T290 along with MEK phosphorylation when associated with A400. Full inhibition of IL-1 induced MEK phosphorylation and partial inhibition of autophosphorylation can occur with a T290A mutation. Partial inhibition of MEK phosphorylation and autophosphorylation has occurred with a T290A or T290E mutation. Partial impairment of MEK phosphorylation induced by IL-1 has been observed with a S400A mutation in Cot. When Cot is associated with A62, a complete loss of T290 and MEK phosphorylation occurs with a S400A mutation. It exists in two forms (approx. 52 kDa and 58 kDa) created by alternative initiation of translation. The C-terminal domain regulates its stability and inhibits its kinase activity; truncation of this domain increases its oncogenic potential. Its activity is regulated by binding to NF- B1 p105, which stabilizes the protein but keeps it inactive. Overexpression of Cot is associated with T-cell lymphomas and mammary carcinomas. This description may include information annotated by UniProt and/or Google AI.